Nivolumab Therapeutic Cheat Sheet
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo …
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo … 
There are many procedural treatments that we have worked on finessing in dermatology, but for some patients with non-melanoma skin cancer, nonsurgical treatments should be discussed. We had the opportunity to review the strengths and weaknesses of nonsurgical treatment approaches for non-melanoma skin cancer and review the indications and future implications of these treatments at ODAC 2023 with D … 
Treatment of malignancy with anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors can cause mucocutaneous side effects resulting from T cell activation. Due to their recent development, the full side effect profile remains to be fully elucidated, however dermatologic adverse events are most common. The main oral toxicities of these immune checkpoint inhibitors include: xerostomia, dysg … 